Yervoy

Selected form

Ipilimumab

Treatment option: Malignant Melanoma

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yervoy

Yervoy is an advanced, prescription-only antineoplastic immunotherapy used for the systemic treatment of certain advanced diseases. Its approach centers on modulating the immune system's function to target disease, a method used in cancer care as an alternative to traditional cytotoxic treatments.

Property	Description
Active ingredient	Ipilimumab (Fully Humanized IgG1 Monoclonal Antibody)
Form	Concentrate for Solution for Infusion
Pharmacological class	Immune Checkpoint Inhibitor (CTLA-4 Inhibitor)
Common use	Systemic treatment for advanced solid tumors
Origin	Biologic, manufactured using Recombinant DNA Technology

Yervoy: Classification as an Immune Checkpoint Inhibitor

Yervoy, containing the active ingredient Ipilimumab, is a first-in-class Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) Inhibitor, placing it within the specialized pharmacological class of Immune Checkpoint Inhibitors. This classification signifies a therapeutic strategy based on immunology, not direct chemical toxicity. This medicine is primarily distinguished by its specific target, CTLA-4, which differentiates its mechanism within the broader class of immunotherapies.

Composition, Form, and Origin of Ipilimumab

The core of Yervoy is Ipilimumab, a highly specialized therapeutic protein. Ipilimumab is a fully humanized IgG1 monoclonal antibody, a type of engineered protein structure that is highly specific to a single target. This biologic is manufactured using recombinant DNA technology in Chinese Hamster Ovary (CHO) cells. The medicine is supplied as a sterile concentrate for solution for infusion and is administered into a vein via the Intravenous (IV) Administration route, reflecting its requirement for hospital or clinic-based administration under specialized care.

General Purpose: Releasing the Immune System's "Brake"

The general purpose of Yervoy is to restore and strengthen the immune system’s ability to mount an antitumor immune response. This function is achieved by binding to the CTLA-4 protein, which acts as a natural checkpoint that slows T-cell activity. By blocking this inhibitory signal, Yervoy releases a constraint, promoting T-cell activation to help the body's defenses engage against abnormal cells.

Regulatory References

Immune Checkpoint Inhibitors (NIH)

What side effects are possible with Yervoy?

Possible Side Effects and Safety Information

Yervoy (ipilimumab) is an Immune Checkpoint Inhibitor whose official safety profile is defined by the risk of immune-mediated adverse reactions (IMARs). These reactions, a direct consequence of the drug's action, are documented in regulatory labeling as potentially severe and fatal, capable of affecting virtually any organ system, including the gastrointestinal tract, liver, and endocrine glands.

Classification of Adverse Reactions

Adverse events are officially classified by their frequency and the System Organ Class (SOC) they affect. The most frequently occurring side effects are categorized as follows, based on official regulatory classifications:

Frequency Category	Representative Examples of Reactions
Very Common (ge 1 in 10 patients)	Fatigue, Pruritus, Rash, Pyrexia, Decreased appetite.
Common (ge 1 in 100 to < 1 in 10 patients)	Diarrhea, Nausea, Vomiting, Abdominal pain, Colitis, Headache, Hypothyroidism.

Serious Adverse Reactions and Safety Patterns

Serious Immune-Mediated Adverse Reactions officially listed include enterocolitis, hepatitis, severe dermatitis (such as Toxic Epidermal Necrolysis), and endocrinopathies like hypophysitis. These events establish the systemic risk of the medicine.

A key characteristic documented in regulatory sources is the time-related safety pattern: IMARs can occur not only during treatment but also weeks to months after the treatment course has been completed. The safety profile also differs when used in combination with other anti-cancer agents, resulting in different risks than when used alone.

For population-specific considerations, official labeling states that the medicine can cause fetal harm and that the safety and effectiveness in the pediatric population have not been established.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Yervoy (ipilimumab) overdose is defined primarily by the risk of severe immune-mediated adverse reactions (IMARs) rather than acute dose toxicity. The maximum tolerated dose has not been determined in clinical trials, and doses higher than therapeutic levels have been administered without apparent toxic effects, according to regulatory documentation.

Documented Manifestations and Emergency Actions

Feature	Regulatory Statement
Overdose Presentation	In a case of overdose, patients must be closely monitored for signs or symptoms of adverse reactions. No specific antidote is known.
Life-Threatening Risk	The primary concern is severe and fatal IMARs, including enterocolitis, hepatitis, and severe dermatitis (toxic epidermal necrolysis), which can affect multiple organ systems.
Action for Urgent Help	Urgent medical attention is required for any severe or life-threatening IMAR. This mandates permanent discontinuation of Yervoy and immediate initiation of systemic high-dose corticosteroid therapy (e.g., prednisone or equivalent) as supportive treatment, per official labeling.
Monitoring	Monitoring and evaluation of clinical chemistries are required before administration, which is critical for detecting severe toxicity requiring emergency intervention.

Conclusion on Seeking Help

The official regulatory guidance establishes that any manifestation of a severe or life-threatening immune-mediated adverse reaction is the definitive condition that requires immediate medical help. These documented events trigger the mandatory treatment protocol of drug cessation and initiation of supportive measures, as specified in the Prescribing Information.

Therapeutic Uses of Yervoy

What Yervoy Treats: Main Uses and Benefits

Yervoy (ipilimumab) is applied across domains where additional symptomatic support is needed, and may be part of symptomatic management, supporting a sustained clinical advantage. The treatment is commonly used for a range of aggressive cancers.

Treatment for Advanced and Metastatic Solid Tumors

This medication is applied in clinical settings that involve acute or unstable symptom patterns where cancer has reached an advanced or metastatic stage or is unresectable (cannot be removed by surgery). It is commonly used for major cancer types, including melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma. The key benefit may be contributing to improved comfort during periods of heightened symptoms, which supports patients in managing symptoms that interfere with daily functioning that arise from symptoms related to systemic imbalance.

Managing Risk of Recurrence and Difficult Contexts

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Yervoy is also relevant in the adjuvant setting for patients with high-risk melanoma who have completed surgical resection. In this context, it may assist with addressing symptom clusters that may become intense or disruptive and is used when the risk of the cancer returning is high. The primary therapeutic benefit here supports the patient during difficult episodes by easing distress. Furthermore, the treatment is considered relevant in challenging clinical scenarios, such as when it is applied as first-line therapy for aggressive cancers or when given after prior systemic treatments have failed. This supports patients, contributing to easing the overall symptom load during periods of increased distress.

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Yervoy

Eligibility for Yervoy (ipilimumab) is determined by official rules documented in governmental regulatory sources, focusing on age, reproductive status, and the presence of certain severe, treatment-related toxicities. This information strictly defines the patient populations for whom the treatment is authorized.

Approved Age Groups

Age Group	Official Regulatory Status
Adults	Established safety and effectiveness across all approved indications.
Pediatric Patients	Approved for those 12 years of age and older for specific indications, including melanoma.
Children Under 12	Safety and effectiveness not established; use is not recommended by regulatory authorities.

Condition-Based Restrictions

Treatment must be permanently discontinued if a patient develops certain severe, life-threatening immune-mediated reactions, which legally define a non-eligible status for continued use. These include Grade 3–5 enterocolitis and severe hepatotoxicity.

Patients with specific medical histories, such as a prior allogeneic hematopoietic stem cell transplant (HSCT), require special consideration and close monitoring due to increased risk of complications.

Pregnancy and Lactation Status

Use during pregnancy is not recommended as Yervoy may cause fetal harm. Women of reproductive potential are advised to use effective contraception. For lactation, women are advised to discontinue nursing during treatment and for a period of three months after the last dose.

What should I know about interactions with other medicines?

Yervoy Interactions with other medicines and products

The interaction profile of Yervoy (ipilimumab) is officially documented by regulatory authorities and focuses primarily on pharmacodynamic interactions related to its function as an immunotherapy, rather than common drug metabolism issues.

Documented Pharmacodynamic Cautions

The most significant caution noted in prescribing information involves the co-administration of Systemic Immunosuppressive Agents, including corticosteroids (such as prednisone or dexamethasone).

Restriction: Regulatory documents state that the use of systemic immunosuppressive agents is not recommended before or during the induction phase of Yervoy treatment. This restriction is based on the potential for these agents to interfere with the intended pharmacodynamic activity and effectiveness of ipilimumab.

Absence of Other Interaction Types

Official regulatory sources confirm the absence of several common drug interaction types, which simplifies the overall profile.

Pharmacokinetic Interactions: As a monoclonal antibody, ipilimumab is cleared via protein catabolism, not through the Cytochrome P450 (CYP) enzyme system. Therefore, no clinically significant CYP-mediated interactions (inhibition or induction) are documented in the labeling.
Contraindications and Timing: No specific medicines or product classes are formally classified as contraindicated combinations due to interaction risk. Furthermore, there are no official requirements for mandatory time separation between Yervoy and other co-administered agents.
Food and Supplements: Regulatory documents contain no specific statements or warnings regarding interactions with food, alcohol, or herbal products.

Mechanism of Action

How Yervoy Works

Molecular Action: Blocking the CTLA-4 Checkpoint

Ipilimumab acts as a competitive antagonist by binding directly to the Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) receptor on T-cells, physically preventing the CTLA-4 molecule from engaging with its B7 ligands. This molecular action interrupts the primary co-inhibitory signaling pathway for T-cell activation.

Cascade: Releasing T-Cell Priming and Expansion

The immediate physiological consequence of blocking CTLA-4 is the enhanced and sustained signaling through the CD28 co-stimulatory receptor. This release from inhibition permits the rapid clonal expansion and priming of T-lymphocytes, leading to an increased population of activated effector T-cells. This biological cascade shifts the systemic immune balance by inducing a T-cell-mediated cytotoxic response that takes time to fully develop.

️ Functional Consequence: Modulation of Immune Tolerance

By interfering with the inhibitory CTLA-4 feedback loop, the mechanism modulates systemic immune tolerance, a functional domain that regulates immune cell aggression. This changes the threshold for T-cell activity, permitting T-cells to execute their cytotoxic functions against the target. The resulting physiological effect is the induction of increased T-cell activation and proliferation that reverses the constraint on T-cell function that is mediated by CTLA-4.

Dosage and Administration Information

How Yervoy is Used: Administration Guidelines

Standard administration of Yervoy (ipilimumab) follows a precise, cyclical, and weight-based protocol. The medicine is supplied as a concentrate for solution for infusion and is administered exclusively via Intravenous (IV) Infusion. This administration method requires a specialized setting, such as a clinic or hospital, and cannot be taken orally.

Dosing and Frequency

Dosing is calculated based on the patient’s body weight and the specific indication. For example, the dose for unresectable or metastatic melanoma monotherapy is typically 3 mg/kg, whereas the adjuvant dose is 10 mg/kg.

Treatment follows a structured course:

Induction Phase: Doses are usually given every 3 weeks for a maximum of four doses.
Maintenance Phase (Adjuvant): Doses transition to a schedule of every 12 weeks for up to three years or until disease recurrence.

Procedural and Course Constraints

Before administration, the concentrate must be diluted to a specific concentration using 0.9% Sodium Chloride or 5% Dextrose. The diluted solution is then administered as a controlled infusion over a period of 30 to 90 minutes, depending on the regimen.

In the event a dose is delayed due to an adverse reaction, the protocol for a missed dose is that it must not be replaced. Furthermore, dose reduction is not recommended for managing adverse reactions; instead, doses are either withheld temporarily or permanently discontinued. No specific dose adjustments are required for older adults or those with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Yervoy

Evidence for Use in Advanced or Unresectable Melanoma

Yervoy was studied for use in advanced or metastatic melanoma. The main research was conducted through large, multi-center randomized controlled trials (RCTs) (Phase 2 and 3). These research examined how Yervoy, either alone or in combination with nivolumab (Opdivo), compared to other standard therapies or control groups. Studies explored several key outcomes reflecting daily functioning or activity level, including overall survival and how long the tumor was documented to be stable or reduced (Progression-Free Survival). Research describes that a number of patients were documented to be alive at the time of follow-up analyses, sometimes extending several years beyond the start of the study. Research highlights changes measured during the study period that indicated an objective response in a portion of the studied population. Studies report how patients reported their experience related to tumor progression over time. Evidence is limited in determining the optimal sequence of using Yervoy and other therapies outside of the specific trial designs. Also, long-term effects are not fully established regarding overall quality of life for all patients who participated in the studies. Results apply only to the populations studied, and the diversity of disease characteristics across all patients means subgroup findings are uncertain in some cases.

Evidence for Use in Adjuvant (Post-Surgery) Treatment of Melanoma

Yervoy was studied for use after melanoma has been completely removed by surgery. This research was evaluated in a large, placebo-controlled Phase 3 trial. The researchers examined outcomes related to systemic or functional imbalance, primarily measuring Recurrence-Free Survival (RFS), which is the time before the cancer returns or new cancer appears. They also monitored overall survival. Research describes the measured time before recurrence observed in the Yervoy group compared to the placebo group. However, the trial design was associated with high rates of patients stopping treatment early due to immune-related adverse events. Follow-up durations were limited in characterizing the long-term experience for patients who were unable to complete the full planned course of treatment. Additionally, the study does not determine how Yervoy compares to other more recent treatments now available for this post-surgery setting, as the comparator was a placebo. Comparative evidence is lacking for newer treatment options.

Evidence for Use in Advanced Renal Cell Carcinoma (RCC)

The combination of Yervoy and nivolumab was studied for use as a starting treatment for advanced kidney cancer. Research was observed in a major randomized trial that compared the combination against a standard targeted therapy. Studies explored outcomes reflecting daily functioning or activity level, with a focus on overall survival for patients in the intermediate- or poor-risk groups. Data show patterns related to overall survival measurements for the combination, and separate measurements were documented for the standard targeted therapy in the same study. Research describes that a greater percentage of patients in the combination group experienced an objective tumor response. Data for certain groups remain insufficient, specifically for patients with favorable-risk advanced kidney cancer, as the primary analysis of the trial focused on those with intermediate or poor risk. The open-label design of the trial means the study was not blinded, which can limit certain insights compared to double-blind research.

Long-Term Studies and Extended Follow-up

Research has explored long-term survival in patients who received Yervoy, with follow-up data available for up to five years or more in the primary studies for melanoma and renal cell carcinoma. Studies contribute to the broader evidence landscape by providing context on extended follow-up that was observed in some studies. Long-term effects are not fully established regarding the consistency of quality-of-life measurements over many years for all study participants. The extended data provides insight into short-term changes but there is limited information for long-term outcomes beyond the set follow-up periods in how the treatment may affect a patient's overall health status.

Evidence in Specific Patient Subgroups

Yervoy was evaluated in research that examined temporary physiological imbalance in specific patient groups. For example, some clinical trials included cohorts of older adults, and separate analyses research examined how treatment was observed in patients with melanoma that had spread to the brain (CNS metastases). Findings were mixed or evidence is limited for specific conditions like use in pediatric populations or in patients with certain pre-existing autoimmune conditions. Data are still emerging from research focused on patients with significant comorbidities, meaning data for certain groups remain insufficient and additional study is needed.

What is Still Uncertain About Yervoy Research

While research has been studied for Yervoy across its approved uses, several questions remain. Comparative evidence is lacking between Yervoy and the newest generation of immunotherapy drugs in certain settings. Questions about how variations in treatment regimen may affect outcomes are not fully established outside of the specific protocols used in the pivotal trials. Evidence is limited in explaining the reasons behind observed response patterns; the factors that influence an individual's response are still emerging. Research is ongoing to address these evidence gaps. Studies help show what has been observed so far, but research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Yervoy (FAQ)

Q: What are the most common side effects people experience with Yervoy infusions?

A: Official drug information reports that the most common adverse reactions (those occurring in 5% or more of patients) are fatigue, diarrhea, pruritus (itching), rash, and colitis (inflammation of the colon). These are often immune-related adverse reactions that are discussed with the healthcare team.

Q: How long after starting Yervoy do people usually notice side effects?

A: Studies indicate that immune-mediated side effects, which are a major characteristic of this treatment, typically occur while the patient is actively receiving the drug. However, it is important to know that these reactions can sometimes begin weeks or even months after the treatment course has been completed.

Q: Does Yervoy make you lose your hair?

A: Regulatory reports confirm that hair loss, or alopecia, has been observed in clinical trials, although it is generally noted as one of the less common side effects. Hair loss is a reported side effect, and any concerns should be raised with a healthcare professional.

Q: Can Yervoy cause joint pain or arthritis-like symptoms?

A: Official safety data lists musculoskeletal pain and arthralgia (joint ache) as common side effects associated with Yervoy. These symptoms are part of the spectrum of immune-mediated reactions and are managed by the treatment team.

Q: Why do doctors check my thyroid function so often while I'm on Yervoy?

A: The drug's mechanism can sometimes trigger immune-mediated endocrinopathies, which are disorders affecting hormone-producing glands. For this reason, official guidelines recommend monitoring thyroid function tests before each dose to detect potential issues like hypothyroidism (underactive thyroid) early.

Q: Why do some people need to take steroids when they are on Yervoy?

A: Corticosteroids are used to suppress the immune response and manage severe immune-mediated reactions, such as enterocolitis. This intervention is necessary to control the heightened immune activity that can affect organ systems.

Q: Can Yervoy cause issues with the liver, and how are those monitored?

A: Yes, Yervoy can potentially cause immune-mediated hepatitis, which is inflammation of the liver. To monitor for this, healthcare providers routinely check liver function through blood tests, specifically looking at transaminase and bilirubin levels before each dose is administered.

Q: Is it safe to get a flu shot or other vaccines while undergoing Yervoy treatment?

A: Official regulatory documents do not provide specific warnings or advice regarding the use of vaccines, such as a flu shot, while being treated with Yervoy. Because this drug changes how the immune system functions, immunizations are a topic for discussion with the supervising healthcare team.

Q: What happens if a dose of Yervoy is missed or delayed?

A: According to the official prescribing information, doses may be delayed temporarily if a patient experiences a moderate immune-mediated adverse reaction. Once the reaction resolves and the patient meets specific health criteria, treatment may be resumed. Dose reduction, however, is generally not recommended for managing side effects.

Q: Can older patients (over 70) safely use Yervoy?

A: Official regulatory information states that no specific dose adjustment is required for patients 65 years of age and older. Clinical studies have not found overall differences in safety or effectiveness between older and younger patients, though older patients may be monitored closely in clinical practice.

Q: What is the success rate of Yervoy for advanced melanoma?

A: Research data from key clinical trials show that a portion of patients experience a long-term benefit. In one major study, approximately 20% of patients with advanced melanoma treated with Yervoy were documented to be alive years after the treatment began, indicating a potential for sustained response in some individuals.

Q: Can Yervoy treatment affect a person's ability to drive or operate machinery?

A: Official safety documents indicate that Yervoy has a minor influence on the ability to drive or use machines. Patients are advised to be cautious, especially if they experience adverse reactions such as fatigue, which could potentially affect concentration.

Q: What are the signs of a serious immune-related side effect from Yervoy that require immediate medical attention?

A: Signs that have been documented to require medical review include severe diarrhea or inflammation of the colon (colitis), new or worsening rash, any yellowing of the skin or eyes (jaundice), or severe, unusual tiredness and mental confusion.

Q: Is it normal to have flu-like symptoms after a Yervoy infusion?

A: Flu-like symptoms are possible, as fatigue and pyrexia (fever) are listed in official documents as very common side effects. Experiencing these symptoms after an infusion is a known possibility and should be reported to the healthcare team.

Q: Can Yervoy be used for cancer that has spread to the brain?

A: Authoritative clinical guidance used by physicians includes Yervoy, sometimes in combination with other immunotherapies, as a treatment option for melanoma that has spread to the brain (known as CNS metastases) in certain clinical settings.

How should Yervoy be stored and disposed of?

Storage and Disposal Conditions for Yervoy (ipilimumab)

The storage of unopened Yervoy vials is strictly mandated. Vials must be kept refrigerated at a temperature range of 2°C to 8°C (36°F to 46°F) and must not be frozen.

Stability and Handling

To ensure protection from light, the vial must remain in its original carton. The product should never be shaken. The prepared, diluted solution is stable for a maximum of 24 hours whether stored refrigerated or at room temperature (20°C to 25°C).

Disposal Requirements

All unused product, waste material, or empty vials must be discarded according to local regulatory requirements for pharmaceutical waste. The medicine must not be disposed of in household waste or wastewater. For child safety, store the product out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.